TROP-2 is involved in regulating cancer growth and invasion in different tumour types. It is also a potent therapeutic target, being addressed by antibody drug conjugates (ADC). This study evaluates the impact of TROP-2 on breast cancer prognosis in high-risk, node-positive BC of the German adjuvant intergroup node-positive (GAIN) cohort.